Non-Alzheimer's Disease Dementias: Anatomic, Clinical, and Molecular Correlates

Canadian Journal of Psychiatry

Volumn 49, Issue 3, 2004, Pages 164-171

  Hou, Craig E ^a,b   Carlin, Danielle ^a   Miller, Brace L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Box 1207 ^*  (United States)

Author keywords

Dementia; Frontotemporal dementia; Review; Synucleinopathy; Tauopathy

Indexed keywords

ALPHA SYNUCLEIN; CARBIDOPA; CHOLINESTERASE INHIBITOR; DONEPEZIL; DOPAMINE; FLUOXETINE; LEVODOPA; MESSENGER RNA; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; RIVASTIGMINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SYNUCLEIN; TAU PROTEIN;

BEHAVIOR DISORDER; BRAIN ATROPHY; BRAIN DEGENERATION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CORRELATION ANALYSIS; CORTICOBASAL DEGENERATION; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FRONTOTEMPORAL LOBAR DEGENERATION; HUMAN; LEWY BODY; MENTAL DISEASE; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MULTISYSTEM ATROPHY; NERVE CONDUCTION; NERVE DEGENERATION; NONHUMAN; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN AGGREGATION; REVIEW; SYMPTOM;

EID: 1942440928     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370404900303     Document Type: Review

References (76)

1. Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, and others. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999;8:711-5.
2. Lynch T, Sano M, Marder KS, Bell KL, Foster NL, Defendini RF, and others. Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology 1994;44:1878-84.
3. Wilhelmsen KC, Lynch T, Pavlou E, Higgins M, Nygaard TG. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. Am J Hum Genet 1994;55:1159-65.
4. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, and others. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702-5.
5. Feany MB, Dickson DW. Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am J Pathol 1995;146:1388-96.
6. Conrad C, Andreadis A, Trojanowski JQ, Dickson DW, Kang D, Chen X, and others. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol 1997;41:277-81.
7. Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S, Adamson J, and others. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001;56:1702-6.
8. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, and others. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-54.
9. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology 2002;58:1615-21.
10. Morita K, Kaiya H, Ikeda T, Namba M. Presenile dementia combined with amyotrophy: a review of 34 Japanese cases. Arch Gerontol Geriatr 1987;6:263-77.
11. Neary D, Snowden JS, Mann DM, Northen B, Goulding PJ, Macdermott N. Frontal lobe dementia and motor neuron disease. J Neurol Neurosurg Psychiatry 1990;53:23-32.
12. Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002;59:1077-9.
13. Hosler BA, Siddique T, Sapp PC, Sailor W, Huang MC, Hossain A, and others. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA 2000;284:1664-9.
14. Caselli RJ, Windebank AJ, Petersen RC, Komori T, Parisi JE, Okazaki H, and others. Rapidly progressive aphasic dementia and motor neuron disease. Ann Neurol 1993;33:200-7.
15. Mesulam MM. Slowly progressive aphasia without generalized dementia. Ann Neurol 1982;11:592-8.
16. Snowden JS, Bathgate D, Varma A, Blackshaw A, Gibbons ZC, Neary D. Distinct behavioural profiles in frontotemporal dementia and semantic dementia. J Neurol Neurosurg Psychiatry 2001;70:323-32.
17. Rosen HJ, Perry RJ, Murphy J, Kramer JH, Mychack P, Schuff N, and others. Emotion comprehension in the temporal variant of frontotemporal dementia. Brain 2002;125:2286-95.
18. Edwards-Lee T, Miller BL, Benson DF, Cummings JL, Russell GL, Boone K, and others. The temporal variant of frontotemporal dementia. Brain 1997;120:1027-40.
19. Mychack P, Kramer JH, Boone KB, Miller BL. The influence of right frontotemporal dysfunction on social behavior in frontotemporal dementia. Neurology 2001;56:S11-S15.
20. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 2001;58:1803-9.
21. Galton CJ, Patterson K, Xuereb JH, Hodges JR. Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain 2000;123:484-98.
22. Kertesz A, Munoz DG. Primary progressive aphasia and Pick complex. J Neurol Sci 2003;206:97-107.
23. Rebeiz JJ, Kolodny EH, Richardson EP Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968;18:20-33.
24. Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain 1989;112:1171-92.
25. Pillon B, Blin J, Vidailhet M, Deweer B, Sirigu A, Dubois B, and others. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer's disease. Neurology 1995;45:1477-83.
26. Grimes DA, Lang AE, Bergeron CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 1999;53:1969-74.
27. Frattali CM, Grafman J, Patronas N, Makblouf F, Litvan I. Language disturbances in corticobasal degeneration. Neurology 2000;54:990-2.
28. Kertesz A, Martinez-Lage P, Davidson W, Munoz DG. The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology 2000;55:1368-75.
29. Boeve BF, Maraganore DM, Parisi JE, Ahlskog JE, Graff-Radford N, Caselli RJ, and others. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999;53:795-800.
30. Horoupian DS, Wasserstein PH. Alzheimer's disease pathology in motor cortex in dementia with Lewy bodies clinically mimicking corticobasal degeneration. Acta Neuropathol (Berl) 1999;98:317-22.
31. Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, and others. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002;61:935-46.
32. Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003;54:S15-S19.
33. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, and others. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
34. Komori T. Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease. Brain Pathol 1999;9:663-79.
35. Mailliot C, Sergeant N, Bussiere T, Caillet-Boudin ML, Delacourte A, Buee L. Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes. FEBS Lett 1998;433:201-4.
36. Liu WK, Le TV, Adamson J, Baker M, Cookson N, Hardy J, and others. Relationship of the extended tau haplotype to tau biochemistry and neuropathology in progressive supranuclear palsy. Ann Neurol 2001;50:494-502.
37. Di Maria E, Tabaton M, Vigo T, Abbruzzese G, Bellone E, Donati C, and others. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann Neurol 2000;47:374-7.
38. Jensen PH, Gai WP. Alpha-synuclein. Axonal transport, ligand interaction and neurodegeneration. Adv Exp Med Biol 2001;487:129-34.
39. Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 1998;273:9443-9.
40. Li JY, Henning Jensen P, Dahlstrom A. Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS. Neuroscience 2002;113:463-78.
41. Tamo W, Imaizumi T, Tanji K, Yoshida H, Mori F, Yoshimoto M, and others. Expression of alpha-synuclein, the precursor of non-amyloid beta component of Alzheimer's disease amyloid, in human cerebral blood vessels. Neurosci Lett 2002;326:5-8.
42. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho W-H, Castillo PE, and others. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000;25:239-52.
43. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, and others. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 2002;22:8797-807.
44. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, and others. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7.
45. Wakabayashi K, Hayashi S, Kakita A, Yamada M, Toyoshima Y, Yoshimoto M, and others. Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol (Berl) 1998;96:445-52.
46. Giasson BI, Uryu K, Trojanowski JQ, Lee VM. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem 1999;274:7619-22.
47. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, and others. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
48. Ballard C, O'Brien J, Gray A, Cormack F, Ayre G, Rowan E, and others. Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease. Arch Neurol 2001;58:977-82.
49. Simard M, van Reekum R, Cohen T. A review of the cognitive and behavioral symptoms in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 2000;12:425-50.
50. Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer's disease and Parkinson's disease comparison groups. Neurology 1996;47:1148-52.
51. Marantz AG, Verghese J. Capgras' syndrome in dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2002;15:239-41.
52. Ballard C, Piggott M, Johnson M, Cairns N, Perry R, McKeith I, and others. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000;48:868-76.
53. Boeve BF, Silber MH, Parisi JE, Dickson DW, Ferman TJ, Benarroch EE, and others. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 2003;61:40-5.
54. Del Ser T, McKeith I, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. Dementia with lewy bodies: findings from an international multicentre study. Int J Geriatr Psychiatry 2000;15:1034-45.
55. Ballard CG, Court JA, Piggott M, Johnson M, O'Brien J, McKeith I, and others. Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex. Conscious Cogn 2002;11:461-74.
56. Burton EJ, Karas G, Paling SM, Barber R, Williams ED, Ballard CG, and others. Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage 2002;17:618-30.
57. Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, and others. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999;122:1449-68.
58. Leverenz JB, Miller MA, Dobie DJ, Peskind ER, Raskind MA. Increased alpha 2-adrenergic receptor binding in locus coeruleus projection areas in dementia with Lewy bodies. Neurobiol Aging 2001;22:555-61.
59. Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 1969;32:28-34.
60. Ghorayeb I, Yekhlef F, Chrysostome V, Balestre E, Bioulac B, Tison F. Sleep disorders and their determinants in multiple system atrophy. J Neurol Neurosurg Psychiatry 2002;72:798-800.
61. Goto K, Ueki A, Shimode H, Shinjo H, Miwa C, Morita Y. Depression in multiple system atrophy: a case report. Psychiatry Clin Neurosci 2000;54:507-11.
62. Fetoni V, Soliveri P, Monza D, Testa D, Girotti F. Affective symptoms in multiple system atrophy and Parkinson's disease: response to levodopa therapy. J Neurol Neurosurg Psychiatry 1999;66:541-44.
63. Berent S, Giordani B, Gilman S, Trask CL, Little RJ, Johanns JR, and others. Patterns of neuropsychological performance in multiple system atrophy compared to sporadic and hereditary olivopontocerebellar atrophy. Brain Cogn 2002;50:194-206.
64. Robbins TW, James M, Lange KW, Owen AM, Quinn NP, Marsden CD. Cognitive performance in multiple system atrophy. Brain 1992;115:271-91.
65. Robbins TW, James M, Owen AM, Lange KW, Lees AJ, Leigh PN, and others. Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. J Neurol Neurosurg Psychiatry 1994;57:79-88.
66. Dickson DW, Liu W, Hardy J, Farrer M, Mehta N, Uitti R, and others. Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol 1999;155:1241-51.
67. Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997;58:212-6.
68. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol 2003;49:13-19.
69. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation. Int J Geriatr Psychiatry 2002;17:391-2.
70. Adler G, Teufel M, Drach LM. Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide. Int J Geriatr Psychiatry 2003;18:653-5.
71. Cummings JL, Mega M, Gray K, Thompson-Rosenberg J, Carusi DA, Gombein J. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14.
72. Stroop J. Studies of interferences in serial verbal reactions. J Exp Psychology 1935;18:643-62.
73. Shea C, MacKnight C, Rockwood K. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998;10:229-38.
74. Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, and others. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 2000;15:794-802.
75. McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D, Stevens T, and others. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 2000;15:387-92.
76. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, and others. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-6.